Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.
Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Incidence rates of lung cancer subtypes vary across global regions, data suggest.
Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.
New research suggests that genetic susceptibility to lung cancer is greater in women, and a family history of cancer predicts lung cancer risk.
Researchers found that patients who used opioids regularly had a roughly 30% higher risk of lung cancer than patients who did not use opioids.
Adding tislelizumab to first-line chemotherapy improved progression-free and overall survival in patients with ES-SCLC in a phase 3 trial.
New research suggests that COVID-19 may be underdiagnosed in patients with lung cancer because mild or asymptomatic SARS-CoV-2 infections are not being reported.